U.S. health regulators announced on Monday that popular weight loss and diabetes medications will now carry a new warning regarding a rare eye condition that can lead to permanent vision loss. The updated labeling applies to all GLP-1 drugs, a blockbuster class of medications used to treat obesity and diabetes that includes well-known brands like Ozempic, Wegovy, Zepbound, and Mounjaro.
New Safety Labels for GLP-1 Medications
The U.S. Food and Drug Administration (FDA) stated that the risk will be integrated into the labeling for a dozen injectable or pill-based medications in the GLP-1 class. This regulatory decision follows an evaluation of data concerning a rare eye problem known as non-arteritic anterior ischemic optic neuropathy, or NAION.
The condition involves decreased blood flow to the optic nerve, though the underlying cause remains not fully understood. While NAION has been reported across all GLP-1 drugs, regulatory scientists initiated their review after a 2024 medical paper linked the condition to certain patients taking semaglutide, the active ingredient in Ozempic and Wegovy.
Clinical Trial Findings and Statistics
An FDA analysis of more than 125 clinical trials revealed that the eye condition occurred in approximately 6 out of every 100,000 patients who used a GLP-1 medication for at least a year. In comparison, the rate for individuals taking a placebo or other glucose-lowering drugs was less than 4 per 100,000.
By comparison, NAION can also develop in individuals who are not taking GLP-1 medications. According to the American Academy of Ophthalmology, the condition affects between 2 and 10 of every 100,000 adults over the age of 50.
Symptoms and Irreversible Effects of NAION
The FDA notes that symptoms of NAION include blurred vision, blind spots, and distorted colors. Patients experiencing these visual disturbances are advised to contact a healthcare professional immediately.
Dr. Joseph Rizzo, a neuro-ophthalmologist who co-authored the 2024 medical study, explained that vision loss from NAION is typically irreversible and can worsen progressively, even if a patient discontinues the medication.
Furthermore, the condition does not necessarily affect both eyes equally. "The degree of visual loss in the first eye does not inform the degree of visual loss that would occur in the second eye," Dr. Rizzo noted. "So you could have mild visual loss in one eye, and then the next eye could be severe."
Despite his findings, Dr. Rizzo does not discourage patients from taking the medications, emphasizing that "the medicines have really been profoundly beneficial to a large number of people."
Manufacturer Responses
Major pharmaceutical companies responded to the FDA safety communication regarding Ozempic, Wegovy, Zepbound, and Mounjaro:
- Novo Nordisk, maker of Ozempic and Wegovy, stated that it believes the data does not establish a direct cause-and-effect relationship and remains confident in the benefit-risk profile of its medications.
- Eli Lilly, maker of Zepbound and Mounjaro, announced it is carefully evaluating the update and will respond to the FDA promptly, noting that the safety communication applies to all medicines with GLP-1 RA activity rather than specific findings for its own products.
Frequently Asked Questions
What eye condition is linked to GLP-1 drugs by the FDA?
The condition is non-arteritic anterior ischemic optic neuropathy, or NAION, which is caused by decreased blood flow to the optic nerve and can result in permanent vision loss.
Are all GLP-1 medications affected by the FDA warning?
Yes, the FDA safety communication applies to all dozen injectable and pill-based drugs within the GLP-1 class, including popular brands like Ozempic, Wegovy, Zepbound, and Mounjaro.
What are the symptoms of NAION that patients should watch for?
Symptoms identified by the FDA include blurred vision, blind spots, distorted colors, and other visual disturbances, which require immediate medical consultation.